Portfolio

Corium International

Develops drug delivery products and devices using proprietary Corplex hydrogel technology


Commercial stage biopharmaceutical company with a transdermal drug delivery platform

Corium (NASDAQ: CORI) is a leader in transdermal delivery systems and related technologies through its platform based on two differentiated, proprietary technologies – MicroCor (large molecules, or biologics, including vaccines, peptides, and proteins) and Corplex (small molecules that are difficult to delivery in transdermal dosage form) – for transporting drugs through the skin for absorption into the body.  The company has a fully functioning GMP production operation in Grand Rapids, MI and has completed development through various stages of FDA filings for several therapeutic products for its partners, with over 180 patents issued, published, and pending related to microstructures, polymers, adhesives, transdermal and other drug delivery technologies.  Corium’s impressive track record of proven development and commercialization capabilities is demonstrated by its partnerships with P&G, Par Pharmaceutical, Teva Pharmaceuticals USA, Agile Therapeutics, amongst others. 

Transaction Summary

  • Essex Woodlands made its first investment in Corium in 2007 and has been a strong partner in building out the commercial operations and pursuing new drug development opportunities.
  • Corium became a public company in April 2014 and Essex continues to hold a significant ownership position.
  • Menlo Park, CA
  • NASDAQ: CORI

  • Contact:
    Ron Eastman
  • www.coriumgroup.com
  • Formerly Known As: Stratagent Life Sciences
  • IPO
  • Acquired by: Gurnet Point Capital
  • Exit date: April 03, 2014
  • Logo

Related News